IP Library › Granted Patent US 10,544,090
Granted Patent B2
US 10,544,090 · App. 14/413,137 · Granted Jan 28, 2020

Anthraquinone analogs and methods of making and using thereof

Inventors: Binghe Wang (Marietta, GA); Chaofeng Dai (Atlanta, GA); Alexander Draganov (Atlanta, GA); Xiaochuan Yang (Baltimore, MD); Guojing Sun (Atlanta, GA); Chunhao Yang (Shanghai, CN); Weixuan Chen (Atlanta, GA); Nanting Ni (Goleta, CA); Muxiang Zhou (Tucker, GA); Lubing Gu (Tucker, GA)
Assignees: Georgia State University Research Foundation, Inc.; Emory University; Children's Healthcare of Atlanta, Inc.
C07C233/33C07C66/02C07C69/95C07C225/36C07C233/31C07C235/16C07C235/84C07C237/04C07C247/04C07C247/10C07C247/12C07C255/19C07C311/08C07C323/60C07D213/56C07D213/61C07D213/70C07D261/08C07D267/12C07D295/15C07D307/54C07D333/24C07C2603/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,544,090
App. No.
14/413,137
Granted
Jan 28, 2020
Kind
B2
Abstract

Rhein analogues that exhibit anti-proliferative activity, particular against cancer cells, are described herein. In some embodiments, the compounds contain a flat or planar ring system. Such rings system by facilitate non-covalent binding of the compounds to the DNA complex, such as by intercalation. In some embodiment, the compounds contain a flat or planar ring system as described above and one or more substituents which are alkylating moieties, electrophilic groups or Michael acceptors or groups which contain one or more alkylating moieties, electrophilic groups and/or Michael acceptors. The compounds described herein can also contain one more functional groups to improve the solubility of the compounds.

Claims (39)

1. A compound having formula:

wherein

X and Y are independently O or S;

W and Z are independently O or S;

R 1 and R 8 are independently substituted or unsubstituted C 1 -C 30 alkyl, substituted or unsubstituted C 2 -C 30 alkenyl, substituted or unsubstituted C 5 -C 7 aryl or arylalkyl;

R 3 is NR 9 —CO—(CH 2 ) n (CH 2 CH 2 O) m R 10 , NR 9 —CO—(CH 2 ) n R 10 , or NR 9 —SO 2 —(CH 2 ) n R 10 , wherein m, n, and o are independently an integer from 0-10 and each occurrence of R 9 is independently hydrogen, C 1 -C 30 alkyl, or C 5 -C 7 aryl, and R 10 is halogen, azide, cyano, C 1 -C 30 alkoxy, aroxy, benzyloxy, trifluoromethyl, vinyl group, hydroxy, amino, primary amine, or secondary amine;

R 2 and R 4 -R 7 are independently hydrogen, —OH, —SH, ether, thioether, primary amine, secondary amine, tertiary amine, ester, carboxylic acid, primary amide, secondary amide, tertiary amide, sulfonyl group, phosphate, nitro, halogen, nitrile, trifluoromethyl, or substituted or unsubstituted C 1 -C 30 alkyl, C 1 -C 30 heteroalkyl, C 2 -C 30 alkenyl, or C 2 -C 30 alkynyl; and

wherein substituents for the substituted groups are independently halogen, hydroxyl, C 1 -C 30 alkyl, C 2 -C 30 alkenyl, C 2 -C 30 alkynyl, phenyl, C 5 -C 7 aryl, C 5 -C 7 heteroaryl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, alkoxy, phenoxy, aroxy, alkylthio, phenylthio, cyano, isocyano, carbonyl, carboxyl, amino, amido, sulfonyl, sulfonic acid, phosphoryl, or phosphonyl.

2. The compound of claim 1 , wherein X, Y, W, and Z are oxygen.

3. The compound of claim 1 , wherein R 1 , R 8 , or both are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, propenyl, benzyl, or (CH 2 ) 3 N 3 .

4. The compound of claim 1 , wherein R 2 and R 4 -R 7 are hydrogen.

5. The compound of claim 1 , wherein R 3 is NHCO(CH 2 ) n R 10 .

6. The compound of claim 1 , wherein R 3 is NH—SO 2 —(CH 2 ) n R 10 .

7. The compound of claim 1 , wherein R 3 is NH—CO—(CH 2 ) n (CH 2 CH 2 O) m R 10 .

8. The compound of claim 1 , wherein R 10 is (CH 2 ) p NHCO(CH 2 ) q halogen or (CH 2 ) p NHCO(CH 2 ) q NH 2 , wherein p and q are independently integers from about 1-6.

9. A pharmaceutical composition comprising one or more compounds of claim 1 and one or more pharmaceutically acceptable carriers.

10. A method of treating leukemia comprising administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of one or more compounds of claim 1 .

11. The compound of claim 1 , wherein the compound is:

12. The compound of claim 1 , wherein X and Y are O, and

wherein R 2 and R 4 -R 7 are independently hydrogen, —OH, —SH, ether, thioether, primary amine, secondary amine, tertiary amine, ester, carboxylic acid, primary amide, secondary amide, tertiary amide, sulfonyl group, phosphate, nitro, halogen, nitrile, trifluoromethyl, or substituted or unsubstituted C 1 -C 30 alkyl or C 1 -C 30 heteroalkyl.

13. The compound of claim 12 , wherein R 2 and R 4 -R 7 are independently hydrogen, —OH, —SH, ether, thioether, primary amine, secondary amine, tertiary amine, ester, carboxylic acid, primary amide, secondary amide, tertiary amide, sulfonyl group, phosphate, nitro, halogen, nitrile, trifluoromethyl, C 1 -C 10 alkyl, or C 1 -C 10 heteroalkyl.

14. The compound of claim 1 , wherein R 2 and R 4 -R 7 are independently hydrogen, —OH, —SH, ether, thioether, primary amine, secondary amine, tertiary amine, ester, carboxylic acid, primary amide, secondary amide, tertiary amide, sulfonyl group, phosphate, nitro, halogen, nitrile, trifluoromethyl, C 1 -C 10 alkyl, or C 1 -C 10 heteroalkyl.

15. The compound of claim 1 , wherein R 2 and R 4 -R 7 are lower alkyl.

16. The compound of claim 1 , wherein R 10 is halogen or azide.

17. The compound of claim 1 , wherein the compound is:

18. A method of treating leukemia comprising administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of one or more compounds having formula:

wherein

X, Y, W, and Z are independently O;

R 1 and R 8 are independently substituted or unsubstituted C 1 -C 30 alkyl, or substituted or unsubstituted arylalkyl;

R 3 is NR 9 —CO—(CH 2 ) n R 10 , wherein n is independently an integer from 0-10 and each occurrence of R 9 is independently hydrogen, C 1 -C 30 alkyl, or C 5 -C 7 aryl, and R 10 is halogen, azide, cyano, C 1 -C 30 alkoxy, aroxy, benzyloxy, trifluoromethyl, vinyl group, hydroxy, amino, primary amine, or secondary amine;

R 2 and R 4 -R 7 are independently hydrogen, —OH, —SH, ether, thioether, primary amine, secondary amine, tertiary amine, ester, carboxylic acid, primary amide, secondary amide, tertiary amide, sulfonyl group, phosphate, nitro, halogen, nitrile, trifluoromethyl, or substituted or unsubstituted C 1 -C 30 alkyl, C 1 -C 30 heteroalkyl, C 2 -C 30 alkenyl, or C 2 -C 30 alkynyl; and

wherein substituents for the substituted groups are independently halogen, hydroxyl, C 1 -C 30 alkyl, C 2 -C 30 alkenyl, C 2 -C 30 alkynyl, phenyl, C 5 -C 7 aryl, C 5 -C 7 heteroaryl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, alkoxy, phenoxy, aroxy, alkylthio, phenylthio, cyano, isocyano, carbonyl, carboxyl, amino, amido, sulfonyl, sulfonic acid, phosphoryl, or phosphonyl.

19. The method of claim 18 , wherein R 1 , R 8 , or both, are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, propenyl, benzyl, or (CH 2 ) 3 N 3 .

20. The method of claim 18 , wherein R 2 and R 4 -R 7 are independently hydrogen, C 1 -C 10 alkyl, or C 1 -C 10 heteroalkyl.

21. The method of claim 18 , wherein R 2 and R 4 -R 7 are hydrogen.

22. The method of claim 18 , wherein n is independently an integer from 1-10.

23. The method of claim 18 , wherein R 3 is NH—CO—(CH 2 ) n R 10 , wherein n is independently an integer from 1-10, and R 10 is halogen, azide, cyano, C 1 -C 30 alkoxy, aroxy, benzyloxy, trifluoromethyl, vinyl group, hydroxy, amino, primary amine, or secondary amine.

24. The method of claim 18 , wherein R 9 is hydrogen.

25. The method of claim 18 , wherein R 10 is halogen or azide.

Continuity (2)
Provisional Application 61669927 · Jul 10, 2012
Related Publication 20150203442A1 · Jul 23, 2015